



COVID-19

Investor briefing

22 March 2022

Disclaimer

This presentation has been prepared by ResApp Health Limited ("ResApp"). The information contained in this presentation is a professional opinion only and is given in good faith. Certain information in this document has been derived from third parties and though ResApp has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by ResApp.

Any forward-looking statements included in this document involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside the control of, and may be unknown to, ResApp. In particular, they speak only as of the date of this document, they assume the success of ResApp's strategies, and they are subject to significant regulatory, business, competitive and economic uncertainties and risks. Actual future events may vary materially from the forward-looking statements and the assumptions on which the forward-looking statements are based. Recipients of this document (Recipients) are cautioned to not place undue reliance on such forward-looking statements. ResApp makes no representation or warranty as to the accuracy, reliability or completeness of information in this document and does not take responsibility for updating any information or correcting any error or omission which may become apparent after this document has been issued.

The information in this presentation is an overview and does not contain all information necessary to make an investment decision. It is intended to constitute a summary of certain information relating to the performance of ResApp. The information in this presentation is of a general nature and does not purport to be complete. This presentation should be read in conjunction with ResApp's other periodic and continuous disclosure announcements, which are available at <https://www.resapphealth.com.au/investor-relations/asx-announcements/>.

To the extent permitted by law, ResApp and its officers, employees, related bodies corporate and agents (Agents) disclaim all liability, direct, indirect or consequential (and whether or not arising out of the negligence, default or lack of care of ResApp and/or any of its Agents) for any loss or damage suffered by a Recipient or other persons arising out of, or in connection with, any use or reliance on this presentation or information.

This presentation is not an offer, invitation, solicitation or recommendation with respect to the subscription for, purchase or sale of any security, and neither this presentation nor anything in it shall form the basis for any contract or commitment whatsoever.

All amounts in Australian dollars unless stated otherwise.

Agenda



COVID-19 research & results

Tony Keating
CEO & Managing Director



Public health context

Professor
Catherine Bennett



Market & commercial strategy

Mike Connell
VP, Commercial

ResApp's COVID-19 scientific advisory board



Prof. Elizabeth Talbot

Geisel School of Medicine
Dartmouth



Prof. Antonio Anzueto

University of Texas Health
San Antonio



Prof. Catherine Bennett

Chair in Epidemiology
Deakin University



Assoc. Prof. Joan Soriano

Hospital Universitario
de la Princesa Madrid



Assoc. Prof. Mark Howard

Director of the Victorian
Respiratory Support Service



Assoc. Prof. Paul Porter

Curtin University & Joondalup
Health Campus

COVID-19

- Coronavirus disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus
- Globally there has been >6m deaths, at a mortality rate estimated to be x10 higher than flu²
- At the peak of Omicron, Australians were waiting for up to 7 days for PCR test results (after waiting in queue for up to 6 hours) and rapid antigen tests were difficult to source³
- PCR and rapid antigen tests generally require a nasal swab as shown (right)
- Rapid antigen tests are widely used to screen and detect COVID-19



Obtaining the Nasopharyngeal Swab Specimen.¹




Global stats⁴



Cases by region

(confirmed)



COVID-19 latest trends



Global conditions perfect for more Covid variants to emerge, WHO's Tedros says

Chloe Taylor
Monday, 24 Jan 2022 12:54 PM EST

WATCH LIVE

- Conditions are ripe for Covid-19 to mutate into more new variants, and it is dangerous to assume the pandemic is approaching its endgame, the WHO's top official warned Monday.
- Last week, an average 100 cases were reported every three seconds, Tedros Adhanom Ghebreyesus added, and someone lost their life to the virus every 12 seconds.
- However, Tedros was optimistic that with the right course of action, the pandemic could reach a turning point in 2022.



Do not assume COVID pandemic reaching 'end game', warns WHO

By Emma Farge and Mrinalika Roy

GENEVA, Jan 24 (Reuters) - The head of the World Health Organization (WHO) warned on Monday that it was dangerous to assume the Omicron variant would herald the end of COVID-19's acutest phase, exhorting nations to stay focused to beat the pandemic.

South Korea reports record Covid deaths as daily cases surge past 600,000

Despite record infections and fatalities, public opinion appears to support plans to ease Covid curbs in the coming days

Read all our coronavirus coverage



Reuters

Thu 17 Mar 2022 17:16 AEDT

How concerning is it that Covid infections are rising in the UK?

Experts say rise was expected but further case increases and new variants are still a threat

Nicola Davis
Science
Correspondent

@NicolaKSDavis

Wed 16 Mar 2022

04:40 AEDT

The Observer
China

With 37 million in lockdown and Covid plans under fire, Chinese ask: what comes next?

Elderly residents are wary of the jab even as Omicron spreads, and critics say zero-Covid policy is not sustainable



A resident is tested for Covid in Changzhou, China. Photograph: Sheldon Cooper/SOPA Images/REX/Shutterstock

Germany hits record Covid infection rate since start of pandemic

Over past 24 hours 262,593 cases have been recorded, but with testing facilities at capacity, number could be higher

Philip
Oltermann in
Berlin

@philipoltermann

Wed 16 Mar 2022 23:24

AEDT

Future public health needs to manage COVID-19



Test Uses



Screening

Diagnostics

Public Health Surveillance Testing

Flexibility for Public Health Management



Variety of tools that facilitate the above

Known strengths and error rates

Confidence in the data we have

Discretion



Use cases will be at the discretion of regulators and public health officials, and will be dependent on local conditions including prevalence, disease severity and resourcing constraints

Leaders in audio based diagnosis of respiratory health

Why our 10 years of experience matters now more than ever



>3,500

cough sounds matched
to gold standard PCR test
results for COVID-19 infection
from studies run in 2021/22



Breathe Easy

the **only** substantial
pre-COVID-19 cough dataset
in the world.

Enables us to be confident that we
are detecting COVID-19, not just
general respiratory disease.



3 Approved Products

CE Marked & TGA approved
products in respiratory disease
diagnosis and screening using
audio

COVID-19 study design



741 Total Participants

US Arm 1:

Decentralised, at-home, partnered with Phosphorus

US Arm 2:

COVID-19 testing clinics, partnered with Covid Clinic

India Arm 1:

COVID-19 testing clinics, partnered with Triomics

India Arm 2:

Mild-moderate hospitalised patients, partnered with Triomics




446
COVID-19
Positive
Participants



Comparator
Gold standard
PCR test
vs coughs
recorded using a
smartphone

Study results



Area under the Curve (AUC)
0.93*


*>0.9 is outstanding³

>90%
Specificity
vs Breathe Easy

Consistent across
study arm and location, age,
gender and vaccination status,
Delta & Omicron variants

COVID-19 mass-screening: *high sensitivity* algorithm

Test with 92% sensitivity, 80% specificity @ 5% incidence of COVID-19



COVID-19 diagnostics, a large and growing market

Potential to expand into patient management and other infectious disease therapy areas



USD105b¹
COVID-19
diagnostic
market
by 2027

COVID-19
patient
management
market

Treatment
companion apps


Other infectious
disease markets

Benefits of a smartphone-based test



Unlimited & instant

Smartphone only
No supply chain issues
Entire test process:
~30 seconds



Non-invasive

Cough sounds only, no
uncomfortable swabs
Likely better compliance



Resource sparing

Reduction in PCR & RAT testing
Savings for governments
insurers and individuals



Environmentally friendly

Reduces manufacturing,
transport, chemicals
& biosecurity waste

Additional options for public health management

Noting these would be at the discretion of public health officials



Flexibility

- Potentially 3 different algorithms (**high sensitivity**, high specificity and balanced) for different use cases.
- **Implementation:** App, SDK and AppClips/Android instant Apps.
- Flexible patient journey instructions post-test.



Security

- Ability to verify test taker and their results via a photograph during the test (eg high risk settings, nursing home visitors etc).



Reporting

- Automated reporting of results to assist in public health management.
- Surveillance programs - de-identified, aggregate level, patient data.

COVID-19 go-to-market: 3 key opportunities

1. Mass screening

Potential reduction in requirement for RAT/PCR tests – direct to consumer, government & insurance payers



2. Surveillance

Public health monitoring of outbreaks, prevalence rates etc

3. Diagnostic

High prevalence, low resource settings (eg LIMIC/emerging markets), high volume situations where RAT/PCR testing is not practical

Strategy: Global exclusive distribution license, instant scale and reach

Value proposition: Infinitely scalable, instant, non-invasive screening test to dramatically reduce COVID-19 rapid antigen and PCR testing, providing significant savings and reduced environmental impact

COVID-19 strategy

Today's announcement



Screening

Instant, better than a temperature check, more scalable than rapid antigen testing

for: Corporates, venues, schools, transport, governments

Future announcement



Managing

Manage mild cases at home (identify severe cases for early intervention and reducing burden on hospitals)

for: Healthcare systems, governments


Future research



Long COVID R&D

Identify and manage long term effects of COVID-19 on patient's lungs (e.g. fibrosis)

ResApp's overall strategy




Future implications of today's announcement



COVID-19 patient management

Enrolment and preliminary data collection completed.

Review of data and algorithm development to follow.



Other infectious diseases

Potential to detect other infectious respiratory diseases – flu, RSV etc.

Global market of USD18Bn by 2026¹.



Pre-pandemic preparedness

Potential to develop candidate algorithms and further POC's to support management of future pandemics.

Next steps



Prospective trial:

Prove our mass screening data in a double-blinded, prospective clinical trial



Regulatory:

Engagement with key regulatory bodies on the data we have, Breathe Easy data context and future development path



Paediatric:

Initiate research in children <18 years



Patient monitoring:

Analyse data and develop algorithms



Commercial Engagement:

Already talking to a number of parties.



Contacts

CEO and Managing Director

Tony Keating

tony@resapphealth.com.au

+61 (0) 430 180 659

VP, Commercial

Mike Connell

mike@resapphealth.com.au

+61 (0) 422 267 219

Executive Director, Corporate Affairs

Brian Leedman

brian@resapphealth.com.au

+61 (0) 412 281 780

ResApp Health Limited

Level 12, 100 Creek Street

Brisbane QLD 4000 Australia

www.resapphealth.com.au

Thank you!